Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients

Background TNBC is an aggressive subset of breast cancer (BC) without specific target therapy. Methods This observational, retrospective study included 45 cases of TNBC. The aim of this study was to evaluate the expression of the AR, E-cadherin and Ki-67 in relation to histological type, time to relapse and overall survival (OS). Immunohistochemistry (IHC) was carried out on formalin-fixed paraffin-embedded tumor samples obtained from patients defined TNBC. Results The AR was positive (IHC >10%) in 26.6%. E-cadherin (CDH1) expression was considered positive if the score was ≥ 2. This expression was negative in 53.3% cases. The Ki-67 index was ≥ 20% in 37.7%. Univariate analyses showed that AR, CDH1 and Ki-67 are significantly associated with OS. Multivariate analysis showed that AR and Ki-67 expression are independent variables associated with OS. The statistical analysis showed that patients with AR negative and Ki-67 positive expression have a significant correlation with poor outcome. Conclusions Our data suggest that the combination of AR and E-cadherin expression as well as Ki-67 status might be useful prognostic markers in TNBC. Hence, these molecular determinants could play an interesting role to classify subgroups of TNBC.

[1]  Qingyuan Zhang,et al.  The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer , 2012, Medical Oncology.

[2]  B. Xie,et al.  The role of androgens in mammary carcinogenesis. , 2001, Italian journal of anatomy and embryology = Archivio italiano di anatomia ed embriologia.

[3]  N. Lin,et al.  Sites of distant recurrence and clinical outcomes in patients with metastatic triple‐negative breast cancer , 2008, Cancer.

[4]  H. Park,et al.  Expression of androgen receptors in primary breast cancer. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  Daniel Birnbaum,et al.  How basal are triple‐negative breast cancers? , 2008, International journal of cancer.

[6]  W. Nelson,et al.  Regulation of cell-cell adhesion by the cadherin-catenin complex. , 2008, Biochemical Society transactions.

[7]  C. Hudis,et al.  Triple-negative breast cancer: an unmet medical need. , 2011, The oncologist.

[8]  T. Tot,et al.  Immunohistochemical study of androgen receptors in breast carcinoma. Evidence of their frequent expression in lobular carcinoma , 2005, Virchows Archiv.

[9]  J. Persijn,et al.  Oestrogen and androgen receptors in breast cancer and response to endocrine therapy. , 1975, British medical journal.

[10]  Charles M. Perou,et al.  Deconstructing the molecular portraits of breast cancer , 2010, Molecular oncology.

[11]  Ian O Ellis,et al.  Prognostic markers in triple‐negative breast cancer , 2007, Cancer.

[12]  Zhongyu Yuan,et al.  Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray , 2012, Medical Oncology.

[13]  T. Petit,et al.  Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. , 2004, European journal of cancer.

[14]  W. Han,et al.  Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer , 2007, BMC Cancer.

[15]  C. Anders,et al.  Stratifying triple-negative breast cancer: which definition(s) to use? , 2011, Breast Cancer Research.

[16]  M. Bracken,et al.  E-cadherin Immunohistochemical Expression as a Prognostic Factor in Infiltrating Ductal Carcinoma of the Breast: a Systematic Review and Meta-Analysis , 2006, Breast Cancer Research and Treatment.

[17]  A. Gown,et al.  Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.

[18]  K. Hess,et al.  DNA mismatch repair gene polymorphisms affect survival in pancreatic cancer. , 2011, The oncologist.

[19]  T. Traina,et al.  Triple-Negative Breast Cancer: Role of the Androgen Receptor , 2010, Cancer journal.

[20]  R. Balleine,et al.  Ki67 and proliferation in breast cancer , 2013, Journal of Clinical Pathology.

[21]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[22]  R. Dickson,et al.  Roles of androgens in the development, growth, and carcinogenesis of the mammary gland , 2002, The Journal of Steroid Biochemistry and Molecular Biology.

[23]  W. Gerald,et al.  Androgen Receptor Levels and Association with PIK3CA Mutations and Prognosis in Breast Cancer , 2009, Clinical Cancer Research.

[24]  L. Carey,et al.  Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. , 2009, Clinical breast cancer.

[25]  L. Carey.  Directed therapy of subtypes of triple-negative breast cancer. , 2010, The oncologist.

[26]  S. Pinder,et al.  E‐cadherin expression in invasive non‐lobular carcinoma of the breast and its prognostic significance , 2005, Histopathology.

[27]  B. Gumbiner,et al.  Regulation of cadherin-mediated adhesion in morphogenesis , 2005, Nature Reviews Molecular Cell Biology.

[28]  Gordon B Mills,et al.  Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer , 2014, Clinical Cancer Research.

[29]  Jack Cuzick,et al.  Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. , 2011, Journal of the National Cancer Institute.

[30]  Debra L Winkeljohn.  Triple-negative breast cancer. , 2008, Clinical journal of oncology nursing.

[31]  Charles M Perou,et al.  Molecular stratification of triple-negative breast cancers. , 2010, The oncologist.

[32]  Robin L. Jones,et al.  The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer , 2009, Breast Cancer Research and Treatment.

[33]  Oleksiy Tsybrovskyy,et al.  Androgen receptor expression in breast cancer patients tested for BRCA1 and BRCA2 mutations , 2010, Histopathology.

[34]  V. Adamo,et al.  Correction: Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients , 2015, PloS one.

[35]  M. Yashiro,et al.  Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at Stage II: usefulness of prognostic markers E-cadherin and Ki67 , 2011, Breast Cancer Research.

[36]  Andres Forero,et al.  Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer , 2013, Clinical Cancer Research.

[37]  C. Perou,et al.  Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  Samuel Leung,et al.  Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype , 2008, Clinical Cancer Research.

[39]  R. Bryan,et al.  Androgen receptors in breast cancer , 1984, Cancer.

[40]  K. Gelmon,et al.  Ki67 in breast cancer: prognostic and predictive potential. , 2010, The Lancet. Oncology.

[41]  Jason I. Herschkowitz,et al.  Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer , 2010, Breast Cancer Research.

[42]  V. Adamo,et al.  Management and treatment of triple-negative breast cancer patients from the NEMESI study: an Italian experience. , 2012, European journal of cancer.

[43]  Charles M. Perou,et al.  Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse , 2011, Breast Cancer Research and Treatment.

[44]  W. Tilley,et al.  Role of the Androgen Receptor in Human Breast Cancer , 2004, Journal of Mammary Gland Biology and Neoplasia.

[45]  Gordon B Mills,et al.  PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors , 2014, Breast Cancer Research.

[46]  Alan Wells,et al.  Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition , 2010, Molecular Cancer.

[47]  P. Fumoleau,et al.  The Paradox of Triple Negative Breast Cancer: Novel Approaches to Treatment , 2012, The breast journal.

[48]  I. Tannock,et al.  Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. , 2014, Journal of the National Cancer Institute.

[49]  Stephen T. C. Wong,et al.  Identification of Prognosis-Relevant Subgroups in Patients with Chemoresistant Triple-Negative Breast Cancer , 2013, Clinical Cancer Research.

[50]  I. Ellis,et al.  Triple‐negative/basal‐like breast cancer: review , 2009, Pathology.

[51]  K. Wakasa,et al.  Significance of E-cadherin expression in triple-negative breast cancer , 2010, British Journal of Cancer.

[52]  Jorge S Reis-Filho,et al.  Triple-negative breast cancer. , 2010, The New England journal of medicine.

[53]  I. Ellis,et al.  Are Triple-Negative and Basal-Like Breast Cancer Synonymous? , 2008, Clinical Cancer Research.

[54]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[55]  L. Carey,et al.  Triple-negative breast cancer: disease entity or title of convenience? , 2010, Nature Reviews Clinical Oncology.

[56]  L. Carey,et al.  What is triple-negative breast cancer? , 2008, European journal of cancer.

[57]  J. Gerdes,et al.  Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. , 1991, The American journal of pathology.